期刊文献+

普伐他汀对冠心病患者血脂、血浆Chemerin水平、超敏C反应蛋白、血清脂联素的影响 被引量:9

Influences of Pravastatin on blood lipid, plasma Chemerin, hs-CRP and serum adiponectin level in patients with coronary heart disease
下载PDF
导出
摘要 目的 探讨普伐他汀对冠心病患者血脂、血浆脂肪因子趋化素(Chemerin)水平、超敏C反应蛋白(hs—CRP)、血清脂联素的影响。方法 收集2010年1月~2013年12月湖北省荣军医院老年病科收治的118例冠心病患者,并将其随机分为常规治疗组和普伐他汀组,观察治疗前后血浆Chemerin水平、hs—CRP、血清脂联素的变化,分析Chemerin、脂联素、hs—CRP与血脂浓度之间的相关性。结果 疗程结束后,普伐他汀组血浆Chemerin、hs—CRP、总胆固醇(TC)、三酰甘油(TG)及低密度脂蛋白胆固醇(LDL—C)水平均较常规治疗组显著降低(P〈0.01),血清脂联素及高密度脂蛋白胆固醇(HDL—C)水平均较常规治疗组显著升高(P〈0.01)。血浆Chemerin与TG呈正相关(r=0.48,P〈0.01);hs—CRP与HDL—C呈负相关(r=-0.21,P〈0.01);血清脂联素与HDL—C呈正相关(r=0.56,P〈0.01),与Chemerin、hs—CRP均呈负相关(r=-0.43、-0.36。P〈0.01)。结论 普伐他汀可以显著降低冠心病患者血脂水平,而且能提高血清脂联素水平以降低hs—CRP浓度及血浆Chemerin水平。 Objective To investigate of blood lipid, plasma Chemerin, hs-CRP and serum adiponectin level in patients with coronary heart disease treated by Pravastatin. Methods 118 patients with coronary heart disease in Hubei Rongjun Hospital from January 2010 to December 2013 were collected and divided into trial group and control group randomly. Changes of blood lipid, plasma Chemerin, hs-CRP and serum adiponeetin level were observed before and after treatment. Relationship of plasma Chemerin, serum levers of adiponectin and hs-CRP with blood lipid were observed. Resuits Level of plasma Chemerin, hs-CRP, TC, TG and LDL-C in trial group were significantly lower than control group (P 〈 0.01). But serum adiponectin and HDL-C level of trial group were higher than control group (P 〈 0.01). The plasma Chemerin concentration was significantly positively correlated with changes in TG (r = 0.48, P 〈 0.01). And hs- CRP was significantly negatively correlated with changes in HDL-C (r = -0.21, P 〈 0.01). The adiponeetin was significantly positively correlated with changes in HDL-C (r = 0.58, P 〈 0.01), but negatively correlated with changes in Chemerin and hs-CRP (r = -0.43, -0.36, P 〈 0.01). Conclusion Pravastatin can dramatically decrease blood lipid and plasma Chemerin level in patients with coronary heart disease. However it can also improve serum adiponeetin levels and decrease hs-CRP level.
作者 张小平
出处 《中国医药导报》 CAS 2014年第15期72-74,共3页 China Medical Herald
基金 湖北省科技厅科技计划项目(项目编号:鄂[2011]JX38321)
关键词 冠心病 普伐他汀 CHEMERIN 超敏C反应蛋白 脂联素 Coronary heart disease Pravastatin Chemerin High-sensitivity C-reactive protein Adiponectin
  • 相关文献

参考文献13

二级参考文献82

共引文献1753

同被引文献98

  • 1陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
  • 2刘春明,孙一帆,梁秀芳.冠心病患者C反应蛋白与血脂联合检测的临床意义[J].检验医学与临床,2007,4(10):968-969. 被引量:10
  • 3王怀玉,董利民,昝青峰,王晨.乳化交联法制备壳聚糖微球粘连原因分析[J].功能材料,2007,38(A05):1923-1925. 被引量:8
  • 4Shin HJ,McCullough PA. Focus on lipids: high-density lipopro-tein cholesterol and its associated lipoproteins in cardiac and re-nal disease[J]. Nephron Clin Pract ,2014,127( 1-4) : 158-164.
  • 5Niccoli G,Conte M,Bone RD, et al. Cystatin C is associatedwith an increased coronary atherosclerotic burden and a stableplaque phenotype in pastients with ischeic heart disease and nor-mal glomerular filtration rate[J]. Atherosclerosis,2008,198(2): 373-380.
  • 6Farnier M, Ducobu J, Bryniarski L. Efficacy and safety ofadding fenofibrate 160 mg in high-risk patients with mixed hy-perlipidemia not controlled by pravastatin 40 mg monotherapy[J]. Am J Cardiol,2010,106(6) :787-792.
  • 7Yilmaz M,Bukan N?Ayvaz G,et al. The effects of rosiglitazoneand metform inonox idative stress and homocyste in elevels inlean patients with polycystic ovary syndrome[J]. Hum Reprod,2005,20 (12 ):3333 -3340.
  • 8Ferraro S, Marano G,Biganzoli EM, et al. Prognostic value ofcystatin C in acute coronary syndromes : enhancer of atheroscle-rosis and promising therapeutic target[J]. Clin Chem Lab Med,2011,49(9)=1397.
  • 9Singh D, Whooley MA,Ix JH. et al. Association of cystatin Candestimated GFR with inflammatory biomarkers : the heart andsoul study[J]. Nephrol Dial Transplant, 2007 ,22(4) : 1087.
  • 10Pitt B,Loscalzo J,Monyak J,et al.Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome(from the LUNAR study)[J].Am J Cardiol,2012,109(9):1239-1246.

引证文献9

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部